Also known as Inati‑cel or CNCT19, this is an autologous, gene‑modified CD19‑directed CAR T‑cell therapy. It is administered as a single IV infusion of 0.2–0.6×10^8 CAR‑T cells (with an optional second infusion at 5–6 months). Patient T cells are engineered to express an anti‑CD19 CAR with CD3ζ/costimulatory signaling, leading to T‑cell activation, proliferation, cytokine release, and cytotoxic killing of CD19+ B‑ALL blasts and normal B cells, aiming to clear minimal residual disease and induce durable B‑cell aplasia.